

Jelle Wesseling

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/6673599/jelle-wesseling-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

245
papers

11,588
citations

56
h-index

98
g-index

272
ext. papers

13,554
ext. citations

6.6
avg, IF

5.79
L-index

#	Paper	IF	Citations
245	Prediction of Upstaging in Ductal Carcinoma in Situ Based on Mammographic Radiomic Features.. <i>Radiology</i> , 2022 , 210407	20.5	1
244	Common variants in breast cancer risk loci predispose to distinct tumor subtypes.. <i>Breast Cancer Research</i> , 2022 , 24, 2	8.3	3
243	Abstract P1-02-09: Results of a worldwide survey on the currently used histopathological diagnostic criteria for invasive lobular breast cancer (ILC). <i>Cancer Research</i> , 2022 , 82, P1-02-09-P1-02-09	10.1	
242	Abstract P1-22-05: Identifying predictors of invasive recurrence based on molecular profiles of DCIS lesions. <i>Cancer Research</i> , 2022 , 82, P1-22-05-P1-22-05	10.1	
241	Prognostic Value of Stromal Tumor-Infiltrating Lymphocytes in Young, Node-Negative, Triple-Negative Breast Cancer Patients Who Did Not Receive (neo)Adjuvant Systemic Therapy.. <i>Journal of Clinical Oncology</i> , 2022 , JCO2101536	2.2	2
240	Comprehensive characterization of pre- and post-treatment samples of breast cancer reveal potential mechanisms of chemotherapy resistance.. <i>Npj Breast Cancer</i> , 2022 , 8, 60	7.8	1
239	Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients.. <i>Lancet Oncology, The</i> , 2021 ,	21.7	16
238	Contralateral parenchymal enhancement on MRI is associated with tumor proteasome pathway gene expression and overall survival of early ER+/HER2-breast cancer patients. <i>Breast</i> , 2021 , 60, 230-237 ^{3.6}		
237	IHC-based Ki67 as response biomarker to tamoxifen in breast cancer window trials enrolling premenopausal women. <i>Npj Breast Cancer</i> , 2021 , 7, 138	7.8	
236	Breast adipocyte size associates with ipsilateral invasive breast cancer risk after ductal carcinoma in situ. <i>Npj Breast Cancer</i> , 2021 , 7, 31	7.8	2
235	Impact of the COVID-19 pandemic on diagnosis, stage, and initial treatment of breast cancer in the Netherlands: a population-based study. <i>Journal of Hematology and Oncology</i> , 2021 , 14, 64	22.4	15
234	Pathologic response of ductal carcinoma in situ to neoadjuvant systemic treatment in HER2-positive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2021 , 189, 213-224	4.4	0
233	Breast-Conserving Therapy in Patients with cT3 Breast Cancer with Good Response to Neoadjuvant Systemic Therapy Results in Excellent Local Control: A Comprehensive Cancer Center Experience. <i>Annals of Surgical Oncology</i> , 2021 , 28, 7383-7394	3.1	0
232	Three-Year Follow-up of Neoadjuvant Chemotherapy With or Without Anthracyclines in the Presence of Dual ERBB2 Blockade in Patients With ERBB2-Positive Breast Cancer: A Secondary Analysis of the TRAIN-2 Randomized, Phase 3 Trial. <i>JAMA Oncology</i> , 2021 , 7, 978-984	13.4	6
231	Treating (low-risk) DCIS patients: What can we learn from real-world cancer registry evidence?. <i>Breast Cancer Research and Treatment</i> , 2021 , 187, 187-196	4.4	3
230	Variability in grading of ductal carcinoma in situ among an international group of pathologists. <i>Journal of Pathology: Clinical Research</i> , 2021 , 7, 233-242	5.3	3
229	Prognostic value of breast MRI characteristics before and during neoadjuvant endocrine therapy in patients with ER+/HER2- breast cancer. <i>British Journal of Radiology</i> , 2021 , 94, 20201125	3.4	

228	Long-term risk of subsequent ipsilateral lesions after surgery with or without radiotherapy for ductal carcinoma in situ of the breast. <i>British Journal of Cancer</i> , 2021 , 125, 1443-1449	8.7	1
227	Impact of the suspension and restart of the Dutch breast cancer screening program on breast cancer incidence and stage during the COVID-19 pandemic. <i>Preventive Medicine</i> , 2021 , 151, 106602	4.3	12
226	The impact of the temporary suspension of national cancer screening programmes due to the COVID-19 epidemic on the diagnosis of breast and colorectal cancer in the Netherlands. <i>Journal of Hematology and Oncology</i> , 2020 , 13, 147	22.4	43
225	De-Escalating Breast Cancer Surgery for Low-Risk Ductal Carcinoma in Situ. <i>JAMA Oncology</i> , 2020 , 6, 1117-1118	13.4	1
224	Radiogenomic Analysis of Breast Cancer by Linking MRI Phenotypes with Tumor Gene Expression. <i>Radiology</i> , 2020 , 296, 277-287	20.5	14
223	Five-Year Results of the Preoperative Accelerated Partial Breast Irradiation (PAPBI) Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020 , 106, 958-967	4	10
222	Personalized early detection and prevention of breast cancer: ENVISION consensus statement. <i>Nature Reviews Clinical Oncology</i> , 2020 , 17, 687-705	19.4	64
221	Endonuclease FEN1 Coregulates ER Activity and Provides a Novel Drug Interface in Tamoxifen-Resistant Breast Cancer. <i>Cancer Research</i> , 2020 , 80, 1914-1926	10.1	10
220	Radiotherapy after primary CHEMotherapy (RAPCHEM): Practice variation in a Dutch registration study (BOOG 2010-03). <i>Radiotherapy and Oncology</i> , 2020 , 145, 201-208	5.3	5
219	The impact of patient characteristics and lifestyle factors on the risk of an ipsilateral event after a primary DCIS: A systematic review. <i>Breast</i> , 2020 , 50, 95-103	3.6	1
218	Somatic mutations and copy number variations in breast cancers with heterogeneous HER2 amplification. <i>Molecular Oncology</i> , 2020 , 14, 671-685	7.9	11
217	Breast Pathology. <i>Encyclopedia of Pathology</i> , 2020 , 175-180	0	
216	Contralateral parenchymal enhancement on breast MRI before and during neoadjuvant endocrine therapy in relation to the preoperative endocrine prognostic index. <i>European Radiology</i> , 2020 , 30, 6740-6748	8	7
215	Prognostic value of histopathological DCIS features in a large-scale international interrater reliability study. <i>Breast Cancer Research and Treatment</i> , 2020 , 183, 759-770	4.4	8
214	BRCAness digitalMLPA profiling predicts benefit of intensified platinum-based chemotherapy in triple-negative and luminal-type breast cancer. <i>Breast Cancer Research</i> , 2020 , 22, 79	8.3	3
213	Cost-effectiveness of Breast Cancer Screening With Magnetic Resonance Imaging for Women at Familial Risk. <i>JAMA Oncology</i> , 2020 , 6, 1381-1389	13.4	14
212	Contralateral breast cancer risk in patients with ductal carcinoma in situ and invasive breast cancer. <i>Npj Breast Cancer</i> , 2020 , 6, 60	7.8	0
211	Response to Preoperative Radiation Therapy in Relation to Gene Expression Patterns in Breast Cancer Patients. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020 , 106, 174-181	4	7

210	Avoiding Overtreatment of Ductal Carcinoma in situ. <i>Trends in Cancer</i> , 2019 , 5, 391-393	12.5	2
209	Dissecting the predictive value of MAPK/AKT/estrogen-receptor phosphorylation axis in primary breast cancer to treatment response for tamoxifen over exemestane: a Translational Report of the Intergroup Exemestane Study (IES)-PathIES. <i>Breast Cancer Research and Treatment</i> , 2019 , 175, 149-163	4.4	3
208	MRI versus mammography for breast cancer screening in women with familial risk (FaMRisc): a multicentre, randomised, controlled trial. <i>Lancet Oncology, The</i> , 2019 , 20, 1136-1147	21.7	57
207	Utility of diagnostic breast excision biopsies during two decades of screening mammography. <i>Breast</i> , 2019 , 46, 157-162	3.6	4
206	Prognostic Value of Residual Disease after Neoadjuvant Therapy in HER2-Positive Breast Cancer Evaluated by Residual Cancer Burden, Neoadjuvant Response Index, and Neo-Bioscore. <i>Clinical Cancer Research</i> , 2019 , 25, 4985-4992	12.9	8
205	EZH2 Is Overexpressed in -like Breast Tumors and Predictive for Sensitivity to High-Dose Platinum-Based Chemotherapy. <i>Clinical Cancer Research</i> , 2019 , 25, 4351-4362	12.9	23
204	Predictors of an Invasive Breast Cancer Recurrence after DCIS: A Systematic Review and Meta-analyses. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2019 , 28, 835-845	4	17
203	Reliability of preoperative breast biopsies showing ductal carcinoma in situ and implications for non-operative treatment: a cohort study. <i>Breast Cancer Research and Treatment</i> , 2019 , 178, 409-418	4.4	13
202	Ductal carcinoma in situ: to treat or not to treat, that is the question. <i>British Journal of Cancer</i> , 2019 , 121, 285-292	8.7	71
201	Are contralateral parenchymal enhancement on dynamic contrast-enhanced MRI and genomic ER-pathway activity in ER-positive/HER2-negative breast cancer related?. <i>European Journal of Radiology</i> , 2019 , 121, 108705	4.7	6
200	Discordant Marker Expression Between Invasive Breast Carcinoma and Corresponding Synchronous and Preceding DCIS. <i>American Journal of Surgical Pathology</i> , 2019 , 43, 1574-1582	6.7	13
199	Clinicopathological Risk Factors for an Invasive Breast Cancer Recurrence after Ductal Carcinoma -A Nested Case-Control Study. <i>Clinical Cancer Research</i> , 2018 , 24, 3593-3601	12.9	23
198	Enrichment of high-grade tumors in breast cancer gene expression studies. <i>Breast Cancer Research and Treatment</i> , 2018 , 168, 327-335	4.4	3
197	Cause-specific Mortality in a Population-based Cohort of 9799 Women Treated for Ductal Carcinoma In Situ. <i>Annals of Surgery</i> , 2018 , 267, 952-958	7.8	31
196	Breast cancer-related deaths according to grade in ductal carcinoma in situ: A Dutch population-based study on patients diagnosed between 1999 and 2012. <i>European Journal of Cancer</i> , 2018 , 101, 134-142	7.5	11
195	Mitotic count can predict tamoxifen benefit in postmenopausal breast cancer patients while Ki67 score cannot. <i>BMC Cancer</i> , 2018 , 18, 761	4.8	4
194	Conventional Pathology Versus Gene Signatures for Assessing Luminal A and B Type Breast Cancers: Results of a Prospective Cohort Study. <i>Genes</i> , 2018 , 9,	4.2	3
193	The association of diabetes mellitus and insulin treatment with expression of insulin-related proteins in breast tumors. <i>BMC Cancer</i> , 2018 , 18, 224	4.8	6

192	Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial. <i>Lancet Oncology, The</i> , 2018 , 19, 1630-1640	21.7	113
191	Adjuvant dose-dense doxorubicin-cyclophosphamide versus docetaxel-doxorubicin-cyclophosphamide for high-risk breast cancer: First results of the randomised MATADOR trial (BOOG 2004-04). <i>European Journal of Cancer</i> , 2018 , 102, 40-48	7.5	6
190	FOXA1 levels are decreased in pleural breast cancer metastases after adjuvant endocrine therapy, and this is associated with poor outcome. <i>Molecular Oncology</i> , 2018 , 12, 1884-1894	7.9	11
189	Trastuzumab in combination with weekly paclitaxel and carboplatin as neo-adjuvant treatment for HER2-positive breast cancer: The TRAIN-study. <i>European Journal of Cancer</i> , 2017 , 74, 47-54	7.5	16
188	Imaging performance in guiding response to neoadjuvant therapy according to breast cancer subtypes: A systematic literature review. <i>Critical Reviews in Oncology/Hematology</i> , 2017 , 112, 198-207	7	18
187	MRI predicts pathologic complete response in HER2-positive breast cancer after neoadjuvant chemotherapy. <i>Breast Cancer Research and Treatment</i> , 2017 , 164, 99-106	4.4	22
186	Breast Cancer Survival of BRCA1/BRCA2 Mutation Carriers in a Hospital-Based Cohort of Young Women. <i>Journal of the National Cancer Institute</i> , 2017 , 109,	9.7	40
185	Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. <i>Nature Genetics</i> , 2017 , 49, 1767-1778	36.3	186
184	Impact of 70-Gene Signature Use on Adjuvant Chemotherapy Decisions in Patients With Estrogen Receptor-Positive Early Breast Cancer: Results of a Prospective Cohort Study. <i>Journal of Clinical Oncology</i> , 2017 , 35, 2814-2819	2.2	24
183	The prognostic value of the tumour-stroma ratio in primary operable invasive cancer of the breast: a validation study. <i>Breast Cancer Research and Treatment</i> , 2017 , 166, 435-445	4.4	25
182	Surgical Upstaging Rates for Vacuum Assisted Biopsy Proven DCIS: Implications for Active Surveillance Trials. <i>Annals of Surgical Oncology</i> , 2017 , 24, 3534-3540	3.1	52
181	Long-term prognosis of young breast cancer patients (≤40 years) who did not receive adjuvant systemic treatment: protocol for the PARADIGM initiative cohort study. <i>BMJ Open</i> , 2017 , 7, e017842	3	7
180	Insertional mutagenesis identifies drivers of a novel oncogenic pathway in invasive lobular breast carcinoma. <i>Nature Genetics</i> , 2017 , 49, 1219-1230	36.3	49
179	The method of detection of ductal carcinoma in situ has no therapeutic implications: results of a population-based cohort study. <i>Breast Cancer Research</i> , 2017 , 19, 26	8.3	9
178	Additional value of F-FDG PET/CT response evaluation in axillary nodes during neoadjuvant therapy for triple-negative and HER2-positive breast cancer. <i>Cancer Imaging</i> , 2017 , 17, 15	5.6	5
177	Finding the balance between over- and under-treatment of ductal carcinoma in situ (DCIS). <i>Breast</i> , 2017 , 31, 274-283	3.6	87
176	-Mutated Estrogen Receptor-Positive Breast Cancer Shows BRCAness, Suggesting Sensitivity to Drugs Targeting Homologous Recombination Deficiency. <i>Clinical Cancer Research</i> , 2017 , 23, 1236-1241	12.9	16
175	Herkennen van inflammatoir mammacarcinoom. <i>Huisarts En Wetenschap</i> , 2017 , 60, 404-406	0.1	1

174	Monitoring tumor response to neoadjuvant chemotherapy using MRI and 18F-FDG PET/CT in breast cancer subtypes. <i>PLoS ONE</i> , 2017 , 12, e0176782	3.7	14
173	Evaluation of the EGFR polymorphism R497K in two cohorts of neoadjuvantly treated breast cancer patients. <i>PLoS ONE</i> , 2017 , 12, e0189750	3.7	3
172	Prognostic value of automated KI67 scoring in breast cancer: a centralised evaluation of 8088 patients from 10 study groups. <i>Breast Cancer Research</i> , 2016 , 18, 104	8.3	44
171	Survival is associated with complete response on MRI after neoadjuvant chemotherapy in ER-positive HER2-negative breast cancer. <i>Breast Cancer Research</i> , 2016 , 18, 82	8.3	12
170	The distribution of ductal carcinoma in situ (DCIS) grade in 4232 women and its impact on overdiagnosis in breast cancer screening. <i>Breast Cancer Research</i> , 2016 , 18, 47	8.3	42
169	Consistency in recognizing microinvasion in breast carcinomas is improved by immunohistochemistry for myoepithelial markers. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2016 , 468, 473-81	5.1	4
168	Very low local recurrence rates after breast-conserving therapy: analysis of 8485 patients treated over a 28-year period. <i>Breast Cancer Research and Treatment</i> , 2016 , 156, 391-400	4.4	33
167	Tumour-specific proline vulnerability uncovered by differential ribosome codon reading. <i>Nature</i> , 2016 , 530, 490-4	50.4	139
166	Defining hip pain trajectories in early symptomatic hip osteoarthritis--5 year results from a nationwide prospective cohort study (CHECK). <i>Osteoarthritis and Cartilage</i> , 2016 , 24, 768-75	6.2	16
165	Neoadjuvant tamoxifen synchronizes ER binding and gene expression profiles related to outcome and proliferation. <i>Oncotarget</i> , 2016 , 7, 33901-18	3.3	11
164	Prediction Model For Extensive Ductal Carcinoma In Situ Around Early-Stage Invasive Breast Cancer. <i>Investigative Radiology</i> , 2016 , 51, 462-8	10.1	8
163	Additional Prone 18F-FDG PET/CT Acquisition to Improve the Visualization of the Primary Tumor and Regional Lymph Node Metastases in Stage II/III Breast Cancer. <i>Clinical Nuclear Medicine</i> , 2016 , 41, e181-6	1.7	11
162	An international study comparing conventional versus mRNA level testing (TargetPrint) for ER, PR, and HER2 status of breast cancer. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2016 , 469, 297-304	5.1	10
161	Mechanisms of Therapy Resistance in Patient-Derived Xenograft Models of BRCA1-Deficient Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2016 , 108,	9.7	108
160	Subsequent risk of ipsilateral and contralateral invasive breast cancer after treatment for ductal carcinoma in situ: incidence and the effect of radiotherapy in a population-based cohort of 10,090 women. <i>Breast Cancer Research and Treatment</i> , 2016 , 159, 553-63	4.4	34
159	Integration of genomic, transcriptomic and proteomic data identifies two biologically distinct subtypes of invasive lobular breast cancer. <i>Scientific Reports</i> , 2016 , 6, 18517	4.9	96
158	High XIST and Low 53BP1 Expression Predict Poor Outcome after High-Dose Alkylating Chemotherapy in Patients with a BRCA1-like Breast Cancer. <i>Molecular Cancer Therapeutics</i> , 2016 , 15, 190-8	6.1	36
157	Sentinel lymph node biopsy can be omitted in DCIS patients treated with breast conserving therapy. <i>Breast Cancer Research and Treatment</i> , 2016 , 156, 517-525	4.4	42

156	Genetic predisposition to ductal carcinoma in situ of the breast. <i>Breast Cancer Research</i> , 2016 , 18, 22	8.3	31
155	Evaluation of a Hanging-Breast PET System for Primary Tumor Visualization in Patients With Stage I-III Breast Cancer: Comparison With Standard PET/CT. <i>American Journal of Roentgenology</i> , 2016 , 206, 1307-14	5.4	25
154	The prognostic value of the neoadjuvant response index in triple-negative breast cancer: validation and comparison with pathological complete response as outcome measure. <i>Breast Cancer Research and Treatment</i> , 2015 , 153, 145-52	4.4	5
153	Fat/water ratios measured with diffuse reflectance spectroscopy to detect breast tumor boundaries. <i>Breast Cancer Research and Treatment</i> , 2015 , 152, 509-18	4.4	46
152	Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration. <i>Annals of Oncology</i> , 2015 , 26, 1280-91	10.3	127
151	First results of the preoperative accelerated partial breast irradiation (PAPBI) trial. <i>Radiotherapy and Oncology</i> , 2015 , 114, 322-7	5.3	44
150	Retrospective analysis of metastatic behaviour of breast cancer subtypes. <i>Breast Cancer Research and Treatment</i> , 2015 , 150, 547-57	4.4	104
149	Feasibility of a prospective, randomised, open-label, international multicentre, phase III, non-inferiority trial to assess the safety of active surveillance for low risk ductal carcinoma in situ - The LORD study. <i>European Journal of Cancer</i> , 2015 , 51, 1497-510	7.5	196
148	Annexin A1 expression in a pooled breast cancer series: association with tumor subtypes and prognosis. <i>BMC Medicine</i> , 2015 , 13, 156	11.4	37
147	Quality assessment of estrogen receptor and progesterone receptor testing in breast cancer using a tissue microarray-based approach. <i>Breast Cancer Research and Treatment</i> , 2015 , 152, 247-52	4.4	16
146	Molecular subtyping improves diagnostic stratification of patients with primary breast cancer into prognostically defined risk groups. <i>Breast Cancer Research and Treatment</i> , 2015 , 154, 81-8	4.4	13
145	Marking axillary lymph nodes with radioactive iodine seeds for axillary staging after neoadjuvant systemic treatment in breast cancer patients: the MARI procedure. <i>Annals of Surgery</i> , 2015 , 261, 378-82	7.8	229
144	Performance of automated scoring of ER, PR, HER2, CK5/6 and EGFR in breast cancer tissue microarrays in the Breast Cancer Association Consortium. <i>Journal of Pathology: Clinical Research</i> , 2015 , 1, 18-32	5.3	18
143	Next generation sequencing of triple negative breast cancer to find predictors for chemotherapy response. <i>Breast Cancer Research</i> , 2015 , 17, 134	8.3	47
142	The use of mass spectrometry imaging to predict treatment response of patient-derived xenograft models of triple-negative breast cancer. <i>Journal of Proteome Research</i> , 2015 , 14, 1069-75	5.6	22
141	Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma. <i>Nature</i> , 2014 , 508, 118-22	50.4	550
140	Phosphorylated p-70S6K predicts tamoxifen resistance in postmenopausal breast cancer patients randomized between adjuvant tamoxifen versus no systemic treatment. <i>Breast Cancer Research</i> , 2014 , 16, R6	8.3	34
139	Reply to "Anti-cytokeratin CAM5.2 recognized CK8 mainly, but not CK18: comment on Early assessment of axillary response with 18F-FDG PET/CT during neoadjuvant chemotherapy in stage II-III breast cancer: implications for surgical management of the axilla. <i>Ann Surg Oncol</i> . 2014;20(7):2227-25" <i>Annals of Surgical Oncology</i> , 2014 , 21, 700	3.1	1

138	Avoiding preoperative breast MRI when conventional imaging is sufficient to stage patients eligible for breast conserving therapy. <i>European Journal of Radiology</i> , 2014 , 83, 273-8	4.7	17
137	Combined use of 18 F-FDG PET/CT and MRI for response monitoring of breast cancer during neoadjuvant chemotherapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014 , 41, 1515-24	8.8	36
136	Optimized outcome prediction in breast cancer by combining the 70-gene signature with clinical risk prediction algorithms. <i>Breast Cancer Research and Treatment</i> , 2014 , 145, 697-705	4.4	19
135	PIK3CA mutations, phosphatase and tensin homolog, human epidermal growth factor receptor 2, and insulin-like growth factor 1 receptor and adjuvant tamoxifen resistance in postmenopausal breast cancer patients. <i>Breast Cancer Research</i> , 2014 , 16, R13	8.3	49
134	Genomic patterns resembling BRCA1- and BRCA2-mutated breast cancers predict benefit of intensified carboplatin-based chemotherapy. <i>Breast Cancer Research</i> , 2014 , 16, R47	8.3	70
133	MammaPrint molecular diagnostics on formalin-fixed, paraffin-embedded tissue. <i>Journal of Molecular Diagnostics</i> , 2014 , 16, 190-7	5.1	81
132	Regulation of TRAIL receptor expression by Ectenin in colorectal tumours. <i>Carcinogenesis</i> , 2014 , 35, 1092-9	4.6	12
131	Distribution pattern of the Ki67 labelling index in breast cancer and its implications for choosing cut-off values. <i>Breast</i> , 2014 , 23, 259-63	3.6	47
130	Lack of genomic heterogeneity at high-resolution aCGH between primary breast cancers and their paired lymph node metastases. <i>PLoS ONE</i> , 2014 , 9, e103177	3.7	9
129	AB0779 7 Years of Follow-Up of Early Symptomatic Oa: Characteristics of CHECK (Cohort HIP & Cohort Knee). <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 1062.1-1062	2.4	
128	Association between rim enhancement of breast cancer on dynamic contrast-enhanced MRI and patient outcome: impact of subtype. <i>Breast Cancer Research and Treatment</i> , 2014 , 148, 541-51	4.4	50
127	Pathological non-response to chemotherapy in a neoadjuvant setting of breast cancer: an inter-institutional study. <i>Breast Cancer Research and Treatment</i> , 2014 , 148, 511-23	4.4	23
126	Upregulation of Claudin-4, CAIX and GLUT-1 in distant breast cancer metastases. <i>BMC Cancer</i> , 2014 , 14, 864	4.8	29
125	Genetic predisposition to in situ and invasive lobular carcinoma of the breast. <i>PLoS Genetics</i> , 2014 , 10, e1004285	6	38
124	PI3K/AKT/mTOR pathway activation in primary and corresponding metastatic breast tumors after adjuvant endocrine therapy. <i>International Journal of Cancer</i> , 2014 , 135, 1257-63	7.5	21
123	Gene expression profiling to predict the risk of locoregional recurrence in breast cancer: a pooled analysis. <i>Breast Cancer Research and Treatment</i> , 2014 , 148, 599-613	4.4	42
122	Radio-guided seed localization for breast cancer excision: an ex-vivo specimen-based study to establish the accuracy of a freehand-SPECT device in predicting resection margins. <i>Nuclear Medicine Communications</i> , 2014 , 35, 961-6	1.6	7
121	Genomic evolution from primary breast carcinoma to distant metastasis: Few copy number changes of breast cancer related genes. <i>Cancer Letters</i> , 2014 , 344, 138-146	9.9	32

120	Sequential (18)F-FDG PET/CT for early prediction of complete pathological response in breast and axilla during neoadjuvant chemotherapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014 , 41, 32-40	8.8	44
119	Performance of automated scoring of ER, PR, HER2, CK5/6 and EGFR in breast cancer tissue microarrays in the Breast Cancer Association Consortium 2014 , n/a-n/a		1
118	A carrier-assisted ChIP-seq method for estrogen receptor-chromatin interactions from breast cancer core needle biopsy samples. <i>BMC Genomics</i> , 2013 , 14, 232	4.5	48
117	Breast cancer subtyping by immunohistochemistry and histological grade outperforms breast cancer intrinsic subtypes in predicting neoadjuvant chemotherapy response. <i>Breast Cancer Research and Treatment</i> , 2013 , 140, 63-71	4.4	67
116	Guiding breast-conserving surgery in patients after neoadjuvant systemic therapy for breast cancer: a comparison of radioactive seed localization with the ROLL technique. <i>Annals of Surgical Oncology</i> , 2013 , 20, 2569-75	3.1	53
115	A prospective evaluation of a breast cancer prognosis signature in the observational RASTER study. <i>International Journal of Cancer</i> , 2013 , 133, 929-36	7.5	163
114	Neoadjuvant chemotherapy adaptation and serial MRI response monitoring in ER-positive HER2-negative breast cancer. <i>British Journal of Cancer</i> , 2013 , 109, 2965-72	8.7	17
113	Early assessment of axillary response with ¹⁸ F-FDG PET/CT during neoadjuvant chemotherapy in stage II-III breast cancer: implications for surgical management of the axilla. <i>Annals of Surgical Oncology</i> , 2013 , 20, 2227-35	3.1	35
112	Platform comparisons for identification of breast cancers with a BRCA-like copy number profile. <i>Breast Cancer Research and Treatment</i> , 2013 , 139, 317-27	4.4	18
111	Paclitaxel, carboplatin, and trastuzumab in a neo-adjuvant regimen for HER2-positive breast cancer. <i>Breast Journal</i> , 2013 , 19, 419-26	1.2	11
110	SERPINA6, BEX1, AGTR1, SLC26A3, and LAPTM4B are markers of resistance to neoadjuvant chemotherapy in HER2-negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2013 , 137, 213-23	4.4	40
109	Diffuse reflectance spectroscopy: towards clinical application in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2013 , 137, 155-65	4.4	36
108	Optical sensing for tumor detection in the liver. <i>European Journal of Surgical Oncology</i> , 2013 , 39, 68-75	3.6	48
107	Does the pretreatment tumor sampling location correspond with metabolic activity on ¹⁸ F-FDG PET/CT in breast cancer patients scheduled for neoadjuvant chemotherapy?. <i>European Journal of Radiology</i> , 2013 , 82, 2353-8	4.7	4
106	Prognostic value of insulin-like growth factor 1 and insulin-like growth factor binding protein 3 blood levels in breast cancer. <i>Breast</i> , 2013 , 22, 1155-60	3.6	24
105	Improved identification of peripheral lung tumors by using diffuse reflectance and fluorescence spectroscopy. <i>Lung Cancer</i> , 2013 , 80, 165-71	5.9	53
104	Triple-negative breast cancer: BRCAness and concordance of clinical features with BRCA1-mutation carriers. <i>British Journal of Cancer</i> , 2013 , 108, 2172-7	8.7	153
103	FDG PET/CT during neoadjuvant chemotherapy may predict response in ER-positive/HER2-negative and triple negative, but not in HER2-positive breast cancer. <i>Breast</i> , 2013 , 22, 691-7	3.6	64

102	Identification of recurrent FGFR3 fusion genes in lung cancer through kinome-centred RNA sequencing. <i>Journal of Pathology</i> , 2013 , 230, 270-6	9.4	94
101	Is DCIS breast cancer, and how do I treat it?. <i>Current Treatment Options in Oncology</i> , 2013 , 14, 75-87	5.4	33
100	Discordance in ER/PR and HER2 receptor status across different distant breast cancer metastases within the same patient. <i>Annals of Oncology</i> , 2013 , 24, 3017-23	10.3	34
99	OP0031 Comparison between check study (cohort hip& cohort knee) and osteoarthritis initiative; development of pain and function in 3 years of follow-up. <i>Annals of the Rheumatic Diseases</i> , 2013 , 71, 63.2-63	2.4	3
98	OP0292 Different Pain Trajectories in Early Symptomatic Knee OA; 5 Year Follow-Up of Check (Cohort Hip & Cohort Knee) Study. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, A152.3-A153	2.4	
97	Molecular evidence in support of the neoplastic and precursor nature of microglandular adenosis. <i>Histopathology</i> , 2012 , 60, E115-30	7.3	42
96	Prevalence and predictors of health care use in patients with early hip or knee osteoarthritis: two-year follow-up data from the CHECK cohort. <i>Osteoarthritis and Cartilage</i> , 2012 , 20, 525-31	6.2	17
95	Somatic mutations in the chromatin remodeling gene ARID1A occur in several tumor types. <i>Human Mutation</i> , 2012 , 33, 100-3	4.7	230
94	Neoadjuvant chemotherapy in ER+ HER2- breast cancer: response prediction based on immunohistochemical and molecular characteristics. <i>Breast Cancer Research and Treatment</i> , 2012 , 131, 827-36	4.4	56
93	Pre-treatment imaging and pathology characteristics of invasive breast cancers of limited extent: potential relevance for MRI-guided localized therapy. <i>Radiotherapy and Oncology</i> , 2012 , 104, 11-8	5.3	15
92	Determining sensitivity and specificity of HER2 testing in breast cancer using a tissue micro-array approach. <i>Breast Cancer Research</i> , 2012 , 14, R93	8.3	43
91	Lobular histology and response to neoadjuvant chemotherapy in invasive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2012 , 136, 35-43	4.4	73
90	Diffuse reflectance spectroscopy: a new guidance tool for improvement of biopsy procedures in lung malignancies. <i>Clinical Lung Cancer</i> , 2012 , 13, 424-31	4.9	36
89	Radioguided occult lesion localisation (ROLL) in breast-conserving surgery after neoadjuvant chemotherapy. <i>European Journal of Surgical Oncology</i> , 2012 , 38, 1218-24	3.6	8
88	Association of primary tumour FDG uptake with clinical, histopathological and molecular characteristics in breast cancer patients scheduled for neoadjuvant chemotherapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012 , 39, 1830-8	8.8	75
87	Prognostic value of estrogen receptor and progesterone receptor conversion in distant breast cancer metastases. <i>Cancer</i> , 2012 , 118, 4929-35	6.4	72
86	MRI of the breast in patients with DCIS to exclude the presence of invasive disease. <i>European Radiology</i> , 2012 , 22, 1504-11	8	24
85	Prediction of BRCA2-association in hereditary breast carcinomas using array-CGH. <i>Breast Cancer Research and Treatment</i> , 2012 , 132, 379-89	4.4	41

84	Clinical correlates of BRCAness in triple-negative breast cancer of patients receiving adjuvant chemotherapy. <i>Annals of Oncology</i> , 2012 , 23, 2301-2305	10.3	28
83	Impact of intertumoral heterogeneity on predicting chemotherapy response of BRCA1-deficient mammary tumors. <i>Cancer Research</i> , 2012 , 72, 2350-61	10.1	41
82	Non-invasive longitudinal imaging of tumor progression using an (111)indium labeled CXCR4 peptide antagonist. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> , 2012 , 2, 99-109	2.2	18
81	Treatment of breast cancer cells by IGF1R tyrosine kinase inhibitor combined with conventional systemic drugs. <i>Anticancer Research</i> , 2012 , 32, 1309-18	2.3	19
80	Immunohistochemical detection of the CXCR4 expression in tumor tissue using the fluorescent peptide antagonist Ac-TZ14011-FITC. <i>Translational Oncology</i> , 2011 , 4, 234-40	4.9	17
79	Distinction of isolated tumour cells and micrometastasis in lymph nodes of breast cancer patients according to the new Tumour Node Metastasis (TNM) definitions. <i>European Journal of Cancer</i> , 2011 , 47, 887-94	7.5	15
78	Effect of bile absorption coefficients on the estimation of liver tissue optical properties and related implications in discriminating healthy and tumorous samples. <i>Biomedical Optics Express</i> , 2011 , 2, 600-14	3.5	55
77	The CYP2C19*2 genotype predicts tamoxifen treatment outcome in advanced breast cancer patients. <i>Pharmacogenomics</i> , 2011 , 12, 1137-46	2.6	38
76	Quantitative copy number analysis by Multiplex Ligation-dependent Probe Amplification (MLPA) of BRCA1-associated breast cancer regions identifies BRCAness. <i>Breast Cancer Research</i> , 2011 , 13, R107	8.3	60
75	Divergent effects of insulin-like growth factor-1 receptor expression on prognosis of estrogen receptor positive versus triple negative invasive ductal breast carcinoma. <i>Breast Cancer Research and Treatment</i> , 2011 , 129, 725-36	4.4	44
74	Implementation of trastuzumab in conjunction with adjuvant chemotherapy in the treatment of non-metastatic breast cancer in the Netherlands. <i>Breast Cancer Research and Treatment</i> , 2011 , 129, 229-33	4.4	32
73	Genomic signature of BRCA1 deficiency in sporadic basal-like breast tumors. <i>Genes Chromosomes and Cancer</i> , 2011 , 50, 71-81	5	47
72	Selective inhibition of microRNA accessibility by RBM38 is required for p53 activity. <i>Nature Communications</i> , 2011 , 2, 513	17.4	83
71	Diagnosis of breast cancer using diffuse optical spectroscopy from 500 to 1600 nm: comparison of classification methods. <i>Journal of Biomedical Optics</i> , 2011 , 16, 087010	3.5	94
70	Magnetic resonance imaging response monitoring of breast cancer during neoadjuvant chemotherapy: relevance of breast cancer subtype. <i>Journal of Clinical Oncology</i> , 2011 , 29, 660-6	2.2	209
69	HER2 gene amplification in patients with breast cancer with equivocal IHC results. <i>Journal of Clinical Pathology</i> , 2011 , 64, 1069-72	3.9	26
68	Indicators of homologous recombination deficiency in breast cancer and association with response to neoadjuvant chemotherapy. <i>Annals of Oncology</i> , 2011 , 22, 870-876	10.3	64
67	Mammary-specific inactivation of E-cadherin and p53 impairs functional gland development and leads to pleomorphic invasive lobular carcinoma in mice. <i>DMM Disease Models and Mechanisms</i> , 2011 , 4, 347-58	4.1	104

66	An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients. <i>Annals of Oncology</i> , 2011 , 22, 1561-1570	10.3	131
65	Symptomatic carrier of haemophilia B Leyden: a case report. <i>Haemophilia</i> , 2010 , 16, 965-6	3.3	1
64	Identification of a low-risk subgroup of HER-2-positive breast cancer by the 70-gene prognosis signature. <i>British Journal of Cancer</i> , 2010 , 103, 1788-93	8.7	56
63	Nodal-stage classification in invasive lobular breast carcinoma: influence of different interpretations of the pTNM classification. <i>Journal of Clinical Oncology</i> , 2010 , 28, 999-1004	2.2	16
62	Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies. <i>PLoS Medicine</i> , 2010 , 7, e1000279	11.6	616
61	The impact of inter-observer variation in pathological assessment of node-negative breast cancer on clinical risk assessment and patient selection for adjuvant systemic treatment. <i>Annals of Oncology</i> , 2010 , 21, 40-7	10.3	48
60	Aggressiveness of true interval invasive ductal carcinomas of the breast in postmenopausal women. <i>Modern Pathology</i> , 2010 , 23, 629-36	9.8	12
59	Receptor conversion in distant breast cancer metastases. <i>Breast Cancer Research</i> , 2010 , 12, R75	8.3	157
58	The role of FDG PET/CT in patients with locoregional breast cancer recurrence: a comparison to conventional imaging techniques. <i>European Journal of Surgical Oncology</i> , 2010 , 36, 387-92	3.6	71
57	Molecular subtyping of breast cancer: ready to use?. <i>Lancet Oncology, The</i> , 2010 , 11, 306-7	21.7	11
56	A simple system for grading the response of breast cancer to neoadjuvant chemotherapy. <i>Annals of Oncology</i> , 2010 , 21, 481-487	10.3	37
55	Prophylactic mastectomy in BRCA1 and BRCA2 mutation carriers: very low risk for subsequent breast cancer. <i>Annals of Surgery</i> , 2010 , 251, 488-92	7.8	63
54	MRI-model to guide the surgical treatment in breast cancer patients after neoadjuvant chemotherapy. <i>Annals of Surgery</i> , 2010 , 251, 701-7	7.8	53
53	Metastatic potential of T1 breast cancer can be predicted by the 70-gene MammaPrint signature. <i>Annals of Surgical Oncology</i> , 2010 , 17, 1406-13	3.1	57
52	The relevance of breast cancer subtypes in the outcome of neoadjuvant chemotherapy. <i>Annals of Surgical Oncology</i> , 2010 , 17, 2411-8	3.1	104
51	The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2010 , 119, 551-8	4.4	195
50	Concordance of clinical and molecular breast cancer subtyping in the context of preoperative chemotherapy response. <i>Breast Cancer Research and Treatment</i> , 2010 , 119, 119-26	4.4	125
49	A practical approach to manage additional lesions at preoperative breast MRI in patients eligible for breast conserving therapy: results. <i>Breast Cancer Research and Treatment</i> , 2010 , 124, 707-15	4.4	34

48	Cell discohesion and multifocality of carcinoma in situ of the bladder: new insight from the adhesion molecule profile (e-cadherin, Ep-CAM, and MUC1). <i>International Journal of Surgical Pathology</i> , 2009 , 17, 99-106	1.2	15
47	CHECK (Cohort Hip and Cohort Knee): similarities and differences with the Osteoarthritis Initiative. <i>Annals of the Rheumatic Diseases</i> , 2009 , 68, 1413-9	2.4	95
46	The impact of preoperative MRI on breast-conserving surgery of invasive cancer: a comparative cohort study. <i>Breast Cancer Research and Treatment</i> , 2009 , 116, 161-9	4.4	91
45	Validation of 70-gene prognosis signature in node-negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2009 , 117, 483-95	4.4	134
44	Phosphorylation of the oestrogen receptor alpha at serine 305 and prediction of tamoxifen resistance in breast cancer. <i>Journal of Pathology</i> , 2009 , 217, 372-9	9.4	49
43	Validation of the 4B5 rabbit monoclonal antibody in determining Her2/neu status in breast cancer. <i>Modern Pathology</i> , 2009 , 22, 879-86	9.8	26
42	Microarray methods to identify factors determining breast cancer progression: potentials, limitations, and challenges. <i>Critical Reviews in Oncology/Hematology</i> , 2009 , 70, 1-11	7	16
41	Towards rational axillary treatment in relation to neoadjuvant therapy in breast cancer. <i>European Journal of Cancer</i> , 2009 , 45, 2284-92	7.5	49
40	Extensive soft tissue resection with autologous tissue closure for locally recurrent breast cancer: lasting local control and acceptable morbidity. <i>European Journal of Surgical Oncology</i> , 2009 , 35, 469-74	3.6	7
39	Expression of insulin-like growth factor system components in colorectal tissue and its relation with serum IGF levels. <i>Growth Hormone and IGF Research</i> , 2009 , 19, 126-35	2	21
38	Accurate axillary lymph node dissection is feasible after neoadjuvant chemotherapy. <i>American Journal of Surgery</i> , 2009 , 198, 46-50	2.7	12
37	Molecular tests for breast-cancer diagnosis?. <i>Lancet Oncology, The</i> , 2009 , 10, 314-5	21.7	
36	Predicting response to alkylating chemotherapy in breast cancer patients using array comparative genomic hybridization. 2009 ,		6
35	Selective benefit of high-dose, platinum-containing, alkylating chemotherapy with stem cell rescue for patients with breast cancers with an expansive growth pattern on histology. <i>Journal of Clinical Oncology</i> , 2009 , 27, 587-587	2.2	2
34	Efficient ways exist to obtain the optimal sample size in clinical trials in rare diseases. <i>Journal of Clinical Epidemiology</i> , 2008 , 61, 324-30	5.7	50
33	Gene expression profiling to identify the histogenetic origin of metastatic adenocarcinomas of unknown primary. <i>Journal of Clinical Oncology</i> , 2008 , 26, 4435-41	2.2	149
32	Measurement of insulin-like growth factor-1 and insulin-like growth factor binding protein-3 after delayed separation of whole blood samples. <i>Clinical Biochemistry</i> , 2008 , 41, 636-9	3.5	8
31	The expression pattern of MUC1 (EMA) is related to tumour characteristics and clinical outcome in pure mucinous carcinoma in situ of the breast. <i>Histopathology</i> , 2007 , 51, 227-38	7.3	21

30	The expression pattern of MUC1 (EMA) is related to tumour characteristics and clinical outcome of invasive ductal breast carcinoma. <i>Histopathology</i> , 2007 , 51, 322-35	7.3	45
29	Pathological and biological differences between screen-detected and interval ductal carcinoma in situ of the breast. <i>Annals of Surgical Oncology</i> , 2007 , 14, 2097-104	3.1	36
28	Increased risk of colorectal neoplasia in asymptomatic liver-transplant recipients. <i>Gut</i> , 2007 , 56, 892-3	19.2	11
27	Differential expression and distribution of epithelial adhesion molecules in non-small cell lung cancer and normal bronchus. <i>Journal of Clinical Pathology</i> , 2007 , 60, 608-14	3.9	47
26	The insulin-like growth factor 1 receptor in cancer: old focus, new future. <i>European Journal of Cancer</i> , 2007 , 43, 1895-904	7.5	147
25	p53 overexpression is a predictor of local recurrence after treatment for both in situ and invasive ductal carcinoma of the breast. <i>Journal of Surgical Research</i> , 2007 , 140, 109-14	2.5	34
24	Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER). <i>Lancet Oncology, The</i> , 2007 , 8, 1079-1087	21.7	217
23	TRAIL induces apoptosis in human colorectal adenoma cell lines and human colorectal adenomas. <i>Clinical Cancer Research</i> , 2006 , 12, 4350-6	12.9	26
22	High ICAM-1 gene expression in pulmonary fibroblasts of COPD patients: a reflection of an enhanced immunological function. <i>European Respiratory Journal</i> , 2006 , 28, 113-22	13.6	24
21	Increased risk of fundic gland polyps during long-term proton pump inhibitor therapy. <i>Alimentary Pharmacology and Therapeutics</i> , 2006 , 24, 1341-8	6.1	173
20	Sarcoidosis mimicking metastatic disease: a case report and review of the literature. <i>Netherlands Journal of Medicine</i> , 2006 , 64, 342-5	0.5	18
19	Phenotypic expression of double heterozygosity for BRCA1 and BRCA2 germline mutations. <i>Journal of Medical Genetics</i> , 2005 , 42, e20	5.8	43
18	Comparison of 18F-FLT PET and 18F-FDG PET in esophageal cancer. <i>Journal of Nuclear Medicine</i> , 2005 , 46, 400-4	8.9	108
17	Tissue distribution of the death ligand TRAIL and its receptors. <i>Journal of Histochemistry and Cytochemistry</i> , 2004 , 52, 821-31	3.4	139
16	Axillary recurrence after sentinel lymph node biopsy. <i>European Journal of Surgical Oncology</i> , 2004 , 30, 715-20	3.6	22
15	Detection of micrometastatic breast cancer by means of real time quantitative RT-PCR and immunostaining in perioperative blood samples and sentinel nodes. <i>International Journal of Cancer</i> , 2003 , 106, 611-618	7.5	38
14	Neurological outcome in school-age children after in utero exposure to coumarins. <i>Early Human Development</i> , 2001 , 63, 83-95	2.2	26
13	Coumarins during pregnancy: long-term effects on growth and development of school-age children. <i>Thrombosis and Haemostasis</i> , 2001 , 85, 609-13	7	13

12	Behavioural outcome of school-age children after prenatal exposure to coumarins. <i>Early Human Development</i> , 2000 , 58, 213-24	2.2	7
11	Membrane-associated mucins. <i>Biomembranes: A Multi-Volume Treatise</i> , 1996 , 219-230		
10	Immunoscintigraphy of small-cell lung cancer xenografts with anti neural cell adhesion molecule monoclonal antibody, 123C3: improvement of tumour uptake by internalisation. <i>British Journal of Cancer</i> , 1996 , 73, 439-46	8.7	10
9	A mechanism for inhibition of E-cadherin-mediated cell-cell adhesion by the membrane-associated mucin episialin/MUC1. <i>Molecular Biology of the Cell</i> , 1996 , 7, 565-77	3.5	337
8	Episialin (MUC1) overexpression inhibits integrin-mediated cell adhesion to extracellular matrix components. <i>Journal of Cell Biology</i> , 1995 , 129, 255-65	7.3	432
7	Is episialin/MUC1 involved in breast cancer progression?. <i>Cancer Letters</i> , 1995 , 90, 27-33	9.9	67
6	Nucleus-associated phosphorylation of Ins(1,4,5)P3 to InsP6 in Dictyostelium. <i>Biochemical Journal</i> , 1995 , 312, 911-917	3.8	18
5	Involvement of the cell surface-bound mucin, episialin/MUC1, in progression of human carcinomas. <i>Biochemical Society Transactions</i> , 1995 , 23, 822-6	5.1	33
4	Cell surface associated mucins: Structure and effects on cell adhesion 1995 , 259-271		3
3	The mucin epiglycanin on TA3/Ha carcinoma cells prevents alpha 6 beta 4-mediated adhesion to laminin and kalinin and E-cadherin-mediated cell-cell interaction. <i>Journal of Cell Biology</i> , 1994 , 127, 2071-780	7.3	61
2	Common variants in breast cancer risk loci predispose to distinct tumor subtypes		1
1	Genomic profiling defines variable clonal relatedness between invasive breast cancer and primary ductal carcinoma in situ		1